Olema Pharmaceuticals, Inc. financial data

Symbol
OLMA on Nasdaq
Industry
Pharmaceutical Preparations
Location
780 Brannan Street, San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24 K % -13.2%
Debt-to-equity 9.08 % +11.1%
Return On Equity -42.9 % +19.5%
Return On Assets -39.3 % +20.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.9 M shares +37.6%
Common Stock, Shares, Outstanding 55.9 M shares +38.2%
Entity Public Float 245 M USD +105%
Common Stock, Value, Issued 4 K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 55.6 M shares +37.7%
Weighted Average Number of Shares Outstanding, Diluted 55.6 M shares +37.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 93.2 M USD +4.61%
General and Administrative Expense 16.5 M USD -31.9%
Operating Income (Loss) -110 M USD +3.21%
Nonoperating Income (Expense) 10.4 M USD +215%
Income Tax Expense (Benefit) 2 K USD +100%
Net Income (Loss) Attributable to Parent -99.3 M USD +9.73%
Earnings Per Share, Basic -2 USD/shares +27%
Earnings Per Share, Diluted -2 USD/shares +27%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.7 M USD -17.6%
Marketable Securities, Current 215 M USD +48.4%
Cash, Cash Equivalents, and Short-term Investments 249 M USD +33.9%
Assets, Current 252 M USD +33.1%
Property, Plant and Equipment, Net 1.03 M USD -25.1%
Operating Lease, Right-of-Use Asset 2.06 M USD -7.43%
Other Assets, Noncurrent 2.77 M USD -0.82%
Assets 264 M USD +34.7%
Accounts Payable, Current 7.66 M USD +1024%
Employee-related Liabilities, Current 983 K USD
Liabilities, Current 26.2 M USD +35.1%
Operating Lease, Liability, Noncurrent 1.15 M USD -16.7%
Liabilities 27.4 M USD +31.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10 K USD +99%
Retained Earnings (Accumulated Deficit) -337 M USD -41.9%
Stockholders' Equity Attributable to Parent 236 M USD +35.1%
Liabilities and Equity 264 M USD +34.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.5 M USD -15.2%
Net Cash Provided by (Used in) Financing Activities 8.82 M USD +3910%
Net Cash Provided by (Used in) Investing Activities -20.1 M USD -154%
Common Stock, Shares Authorized 490 M shares 0%
Common Stock, Shares, Issued 55.9 M shares +37.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -34.8 M USD -302%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.7 M USD -17.6%
Deferred Tax Assets, Valuation Allowance 71.6 M USD +50.9%
Deferred Tax Assets, Gross 71.9 M USD +50.4%
Operating Lease, Liability 2.21 M USD -3.58%
Payments to Acquire Property, Plant, and Equipment 153 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -98.4 M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid 2.41 M USD -5.49%
Property, Plant and Equipment, Gross 1.75 M USD -7.1%
Operating Lease, Liability, Current 1.06 M USD +16.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 263 K USD -68%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.25 M USD +55.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 201 K USD -22.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 263 K USD -68%
Deferred Tax Assets, Operating Loss Carryforwards 44.7 M USD +62.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 69 K USD -91.6%
Operating Lease, Payments 1.17 M USD -9.34%
Additional Paid in Capital 573 M USD +38.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 88 K USD -12%
Share-based Payment Arrangement, Expense 17.5 M USD -5.19%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%